Caring for Patients with Blood Cancer in the Hispanic Community: From Diagnosis Through Survivorship

Continuing Education Information:
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Method of Participation
Participants must view the program, provide their contact information and license number, complete the post-assessment with a score of 70% or higher, and complete the activity evaluation in order to obtain CE credit. After completing this process you will receive your certificate by email.

Continuing education credit is provided free of charge.

Target Audience:
This activity is intended for nurses and other healthcare professionals involved in the care of patients treated for or survivors of a blood cancer.

Learning Objectives:
After completing this activity, the participant should be better able to:

Describe the different blood cancers, including diagnosis and treatment
Describe survivorship issues that may arise in the treatment journey of Hispanic blood cancer patients and the impact on quality of life
Explain the nurse's role in monitoring and managing short- and long-term side-effects, including follow-up care for chronic diagnoses
Review resources from The Leukemia & Lymphoma Society for patients and healthcare providers

Faculty:
Susana Moscoso, BA, BSN, RN, BMT-CN
Clinical Trial Support Center (CTSC) Nurse Navigator
The Leukemia & Lymphoma Society

Providers:
This activity is provided by The Leukemia & Lymphoma Society (LLS) in collaboration with the National Association of Hispanic Nurses.

Disclaimer:
The information provided in this activity is for educational purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Estimated time to complete activity: 1.0 hour
Date of initial release: February 29, 2024
Date of expiration: September 3, 2025


Continuing Education Information: Registered Nursing Credit Designation Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing. Method of Participation Participants must view the program, provide their contact information and license number, complete the post-assessment with a score of 70% or higher, and complete the activity evaluation in order to obtain CE credit. After completing this process you will receive your certificate by email. Continuing education credit is provided free of charge. Target Audience: This activity is intended for nurses and other healthcare professionals involved in the care of patients treated for or survivors of a blood cancer. Learning Objectives: After completing this activity, the participant should be better able to: Describe the different blood cancers, including diagnosis and treatment Describe survivorship issues that may arise in the treatment journey of Hispanic blood cancer patients and the impact on quality of life Explain the nurse's role in monitoring and managing short- and long-term side-effects, including follow-up care for chronic diagnoses Review resources from The Leukemia & Lymphoma Society for patients and healthcare providers Faculty: Susana Moscoso, BA, BSN, RN, BMT-CN Clinical Trial Support Center (CTSC) Nurse Navigator The Leukemia & Lymphoma Society Providers: This activity is provided by The Leukemia & Lymphoma Society (LLS) in collaboration with the National Association of Hispanic Nurses. Disclaimer: The information provided in this activity is for educational purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred. Estimated time to complete activity: 1.0 hour Date of initial release: February 29, 2024 Date of expiration: September 3, 2025